Roche said to have rekindled interest in BioMarin Pharmaceutical - sources
Swiss pharmaceuticals giant Roche has once again been studying a multi-billon dollar purchase of American rare disease specialist BioMarin Pharmaceutical, according to two sources familiar with the matter.
I understand that, so far, the majority of work and analysis on BioMarin has been carried out by Roche's own executives, led by Boris Zaitra, head of M&A...
Register
Register for free to see rest of this article and all public articles from Betaville
Login / RegisterDate: Wednesday, 6 July 2016, 12:00 am